Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report)'s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.80 and traded as high as $0.85. Atossa Genetics shares last traded at $0.82, with a volume of 684,773 shares traded.
Wall Street Analyst Weigh In
A number of analysts recently commented on the company. Ascendiant Capital Markets lifted their price objective on Atossa Genetics from $7.25 to $7.50 and gave the stock a "buy" rating in a research report on Friday, June 6th. Craig Hallum upgraded Atossa Genetics to a "strong-buy" rating and set a $4.00 price objective for the company in a research report on Thursday, June 5th.
Check Out Our Latest Analysis on Atossa Genetics
Atossa Genetics Price Performance
The company has a 50-day moving average of $0.85 and a two-hundred day moving average of $0.80. The stock has a market capitalization of $101.66 million, a PE ratio of -3.75 and a beta of 0.92.
Atossa Genetics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, research analysts forecast that Atossa Genetics Inc. will post -0.22 EPS for the current fiscal year.
Institutional Investors Weigh In On Atossa Genetics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd acquired a new stake in shares of Atossa Genetics in the second quarter valued at about $321,000. Renaissance Technologies LLC grew its stake in shares of Atossa Genetics by 18.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,557,632 shares of the company's stock valued at $1,471,000 after buying an additional 247,562 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Atossa Genetics by 141.4% in the fourth quarter. JPMorgan Chase & Co. now owns 361,296 shares of the company's stock valued at $341,000 after buying an additional 211,654 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Atossa Genetics in the first quarter valued at about $115,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Atossa Genetics by 40.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company's stock valued at $284,000 after buying an additional 120,934 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.
Atossa Genetics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Further Reading
Before you consider Atossa Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Genetics wasn't on the list.
While Atossa Genetics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access